{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:02:58Z","timestamp":1792292578589,"version":"4.4.0"},"reference-count":152,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with nearly one quarter of patients presenting with metastatic disease at diagnosis. The epidermal growth factor receptor (EGFR) plays a central role in CRC pathogenesis through activation of downstream RAS\/RAF\/MAPK and PI3K\/AKT\/mTOR signaling pathways, and has become a major therapeutic target. Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have demonstrated survival benefit in selected patients, particularly those with left-sided, RAS wild-type tumors. However, primary and acquired resistance limit their efficacy, underscoring the need for predictive biomarkers and novel strategies. This review synthesizes current knowledge of EGFR biology, therapeutic integration, and biomarker development, including RAS and BRAF mutations, MSI status, HER2 amplification, EGFR ligands (AREG\/EREG), consensus molecular subtypes, and liquid biopsy applications. We also discuss mechanisms of resistance such as pathway reactivation, receptor mutations, and epithelial-to-mesenchymal transition, alongside emerging approaches, including combination regimens, ctDNA-guided rechallenge, and genotype-specific inhibitors. Collectively, these insights highlight the evolving landscape of precision oncology in CRC and the importance of molecular stratification to optimize EGFR-targeted therapy and overcome resistance.<\/jats:p>","DOI":"10.3390\/ijms27073265","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:06:21Z","timestamp":1775441181000},"page":"3265","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2894-4524","authenticated-orcid":false,"given":"Noura","family":"Abbas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Smaily","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-4383","authenticated-orcid":false,"given":"Layal","family":"Al Mahmasani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-8403","authenticated-orcid":false,"given":"Ali","family":"Shamseddine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"937","article-title":"de novo metastases in patients with primary colorectal cancer: A Surveillance, Epidemiology, and End Results analysis","volume":"36","author":"Sankar","year":"2025","journal-title":"Cancer Causes Control"},{"key":"ref_3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2468-1253(23)00479-X","article-title":"Targeting the EGFR signalling pathway in metastatic colorectal cancer","volume":"9","author":"Napolitano","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer","volume":"360","author":"Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab\u2013FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Committee","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_9","unstructured":"Network, N.C.C. (2026, January 29). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Colon Cancer, Version 5.2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"ref_10","unstructured":"Network, N.C.C. (2026, January 29). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae), Rectal Cancer, Version 4.2025. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., and Gao, Y. (2023). Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11600-z"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/S0021-9258(19)83739-0","article-title":"Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal","volume":"237","author":"Cohen","year":"1962","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"MSB4100014","DOI":"10.1038\/msb4100014","article-title":"A comprehensive pathway map of epidermal growth factor receptor signaling","volume":"1","author":"Oda","year":"2005","journal-title":"Mol. Syst. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/13543781003593962","article-title":"Colorectal cancer in review: The role of the EGFR pathway","volume":"19","author":"Saif","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2015.08.012","article-title":"Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer","volume":"97","author":"Mirone","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: Recent advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Research"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/onco4040019","article-title":"Exploring the Potential of Epiregulin and Amphiregulin as Prognostic, Predictive, and Therapeutic Targets in Colorectal Cancer","volume":"4","author":"High","year":"2024","journal-title":"Onco"},{"key":"ref_20","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"MSB4100012","DOI":"10.1038\/msb4100012","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol. Syst. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1091\/mbc.e05-12-1104","article-title":"Grb2 is a negative modulator of the intrinsic RAS-GEF activity of hSos1","volume":"17","author":"Zarich","year":"2006","journal-title":"Mol. Biol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/rp.56.1.127","article-title":"RAS activation of the RAF kinase: Tyrosine kinase recruitment of the MAP kinase cascade","volume":"56","author":"Avruch","year":"2001","journal-title":"Recent Prog. Horm. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","article-title":"PI3K\/Akt\/mTOR pathway as a target for cancer therapy","volume":"16","author":"Morgensztern","year":"2005","journal-title":"Anti-Cancer Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jcb.21475","article-title":"STAT-mediated EGFR signaling in cancer","volume":"102","author":"Quesnelle","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, P., and Huang, D. (2024). Targeting the JAK-STAT pathway in colorectal cancer: Mechanisms, clinical implications, and therapeutic potential. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1507621"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gargalionis, A.N., Papavassiliou, K.A., and Papavassiliou, A.G. (2021). Targeting STAT3 Signaling Pathway in Colorectal Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081016"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbrc.2021.09.012","article-title":"Phospholipase C\u03b31 represses colorectal cancer growth by inhibiting the Wnt\/\u03b2-catenin signaling axis","volume":"577","author":"Shin","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.critrevonc.2012.11.009","article-title":"Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis","volume":"86","author":"Wu","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_31","first-page":"S71","article-title":"Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer","volume":"5","author":"Snyder","year":"2005","journal-title":"Clin. Color. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-16-0383","article-title":"EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer","volume":"15","author":"Okada","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1200\/jco.2006.24.18_suppl.3548","article-title":"Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing \u2265 10% epidermal growth factor receptor (EGFr)","volume":"24","author":"Berlin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","article-title":"Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: A systematic review and pooled analysis of randomised trials","volume":"184","author":"Rossini","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cam4.2747","article-title":"Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis","volume":"9","author":"Bylsma","year":"2020","journal-title":"Cancer Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.6004\/jnccn.2017.0038","article-title":"Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes","volume":"15","author":"Lee","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/EDBK_349561","article-title":"The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer","volume":"42","author":"Tabernero","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104741","DOI":"10.1016\/j.critrevonc.2025.104741","article-title":"KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials","volume":"211","author":"Akkus","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.2012.43.6535","article-title":"Hurdles and complexities of codon 13 KRAS mutations","volume":"30","author":"Morelli","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_53","first-page":"4673","article-title":"RAS mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma","volume":"30","author":"Dempke","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.18632\/oncotarget.14012","article-title":"Mechanisms of resistance to anti-EGFR therapy in colorectal cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: The PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"113396","DOI":"10.1016\/j.ejca.2023.113396","article-title":"Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU\/LV","volume":"195","author":"Pietrantonio","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2023.41.4_suppl.11","article-title":"Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial","volume":"41","author":"Shitara","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e2200037","DOI":"10.1200\/PO.22.00037","article-title":"Negative Ultraselection of Patients With RAS\/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy","volume":"6","author":"Randon","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Rachiglio, A.M., Lambiase, M., Fenizia, F., Roma, C., Cardone, C., Iannaccone, A., De Luca, A., Carotenuto, M., Frezzetti, D., and Martinelli, E. (2019). Genomic Profiling of KRAS\/NRAS\/BRAF\/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers, 11.","DOI":"10.3390\/cancers11060859"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s12094-025-03887-0","article-title":"HER2-targeted therapy in colorectal cancer: A comprehensive review","volume":"27","author":"Benli","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamaoncol.2015.6065","article-title":"Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer","volume":"2","author":"Seligmann","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1158\/1078-0432.CCR-23-1954","article-title":"Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer","volume":"29","author":"Randon","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"55890","DOI":"10.18632\/oncotarget.10151","article-title":"Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients","volume":"7","author":"Jing","year":"2016","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-20-2748","article-title":"Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials","volume":"26","author":"Stahler","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2200422","DOI":"10.1200\/PO.22.00422","article-title":"Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer","volume":"7","author":"Chowdhury","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41698-025-00892-y","article-title":"Multidimensional differences of right- and left-sided colorectal cancer and their impact on targeted therapies","volume":"9","author":"Pammer","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1634\/theoncologist.2017-0621","article-title":"Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer","volume":"23","author":"Nakamura","year":"2018","journal-title":"Oncologist"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","article-title":"Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer","volume":"29","author":"Patelli","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ciappina, G., Toscano, E., Ottaiano, A., Capuozzo, M., Consolo, P., Maiorana, E., Carroccio, P., Franchina, T., Ieni, A., and Di Mauro, A. (2025). Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052216"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","article-title":"Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer","volume":"28","author":"Grasselli","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1200\/JCO.2025.43.4_suppl.237","article-title":"Clinical relevance of tumor fraction assessment from circulating tumor DNA in metastatic colorectal cancer","volume":"43","author":"Morris","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Germani, M.M., Vetere, G., Giordano, M., Cirac\u00ec, P., Capone, I., Tamborini, E., Conca, E., Busico, A., Pietrantonio, F., and Piva, V.M. (2023). Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: Preliminary data from the randomized phase 2 PARERE trial. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1307545"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1078-0432.CCR-22-1696","article-title":"Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study","volume":"29","author":"Vidal","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/j.annonc.2022.04.208","article-title":"P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study","volume":"33","author":"Salva","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/jnci\/djaf229","article-title":"Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study","volume":"117","author":"Zaanan","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1038\/s44321-025-00332-1","article-title":"Closing the loop on EGFR therapy: Decoding cetuximab response through circ-EGFR","volume":"17","author":"Pilati","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.3748\/wjg.v22.i28.6345","article-title":"Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer","volume":"22","author":"Sforza","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_83","first-page":"203","article-title":"Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer","volume":"14","author":"Lee","year":"2015","journal-title":"Clin. Color. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","article-title":"Expression of epiregulin and amphiregulin and -KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab","volume":"25","author":"Garrett","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"Normanno","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: The first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","first-page":"4682","article-title":"RAS oncogenes in human cancer: A review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1947601911411084","article-title":"RAS in cancer and developmental diseases","volume":"2","author":"Santos","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Folprecht","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Lenz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of -BRAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3748\/wjg.v10.i11.1569","article-title":"Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma","volume":"10","author":"Ma","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Abbas, N., Zahreddine, L., Tawil, A., Natout, M., and Shamseddine, A. (2024). An Atypical Case of Pancreatic Cancer with Mesenchymal Differentiation in a Patient with Primary Lung Adenocarcinoma: Insights into Tumor Biology and Novel Therapeutic Pathways. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222512"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1535-7163.MCT-06-0462","article-title":"Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition","volume":"6","author":"Buck","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_103","first-page":"3735","article-title":"Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelial-mesenchymal transition","volume":"20","author":"Lin","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1038\/s41598-019-51981-5","article-title":"Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients","volume":"9","author":"Bray","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.molonc.2014.05.003","article-title":"Acquired resistance to EGFR-targeted therapies in colorectal cancer","volume":"8","author":"Siena","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909709018911","article-title":"Insulin-like growth factor I receptor messenger RNA in the colon is unchanged during neoplasia","volume":"15","author":"Zenilman","year":"1997","journal-title":"Cancer Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/jnci\/92.18.1472","article-title":"Role of the insulin-like growth factor family in cancer development and progression","volume":"92","author":"Yu","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1158\/0008-5472.CAN-08-0280","article-title":"Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor","volume":"68","author":"Hu","year":"2008","journal-title":"Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1210\/en.2002-220620","article-title":"Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells","volume":"144","author":"Knowlden","year":"2003","journal-title":"Endocrinology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.2007.11.5022","article-title":"Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy","volume":"25","author":"Scartozzi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: Rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"R\u00edos-Hoyo, A., Monzon\u00eds, X., Vidal, J., Linares, J., and Montagut, C. (2024). Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: A long and winding road. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1398419"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer","volume":"21","author":"Arena","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Sickmier, E.A., Kurzeja, R.J., Michelsen, K., Vazir, M., Yang, E., and Tasker, A.S. (2016). The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163366"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-07-4905","article-title":"Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells","volume":"14","author":"Bianco","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e245635","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS\/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_123","first-page":"28","article-title":"Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis","volume":"56","author":"Saldanha","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_124","first-page":"9","article-title":"Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"56","author":"Priantti","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator\u2019s Choice in Chemorefractory KRAS G12C Colorectal Cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Machmouchi, A., Chehade, L., Temraz, S., and Shamseddine, A. (2023). Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030678"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_129","first-page":"TPS326","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C\u2013mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Metzger, B., Chambeau, L., Begon, D.Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., and Dicato, M. (2011). The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Med. Genet., 12.","DOI":"10.1186\/1471-2350-12-144"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/15384047.2020.1798695","article-title":"Frequency of S492R mutations in the epidermal growth factor receptor: Analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy","volume":"21","author":"Price","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdt236","article-title":"A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: The Nordic ACT Trial","volume":"24","author":"Johnsson","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_134","first-page":"90","article-title":"A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study","volume":"3","author":"Frank","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4251\/wjgo.v15.i10.1829","article-title":"Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report","volume":"15","author":"Buzard","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"oyae113","DOI":"10.1093\/oncolo\/oyae113","article-title":"Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors","volume":"30","author":"Kondo","year":"2025","journal-title":"Oncologist"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: Pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_138","first-page":"572","article-title":"Overcoming the hurdles: Surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer","volume":"21","author":"Sackstein","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Leiphrakpam, P.D., and Are, C. (2024). PI3K\/Akt\/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063178"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO-24-01710","article-title":"Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS\/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial","volume":"43","author":"Raghav","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_142","first-page":"256","article-title":"Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin. Color. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial","volume":"5","author":"Lonardi","year":"2020","journal-title":"ESMO Open"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","article-title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: A phase 2 trial","volume":"27","author":"Nakamura","year":"2021","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1158\/1078-0432.CCR-10-0568","article-title":"HGF rescues colorectal cancer cells from EGFR inhibition via MET activation","volume":"17","author":"Liska","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Leite, L.F., Noronha, M.M., de Menezes, J.S.A., da Concei\u00e7\u00e3o, L.D., Almeida, L.F.C., Cappellaro, A.P., Belotto, M., Biachi de Castria, T., Peixoto, R.D.A., and Megid, T.B.C. (2025). Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Cancers, 17.","DOI":"10.3390\/cancers17172804"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"324ra314","DOI":"10.1126\/scitranslmed.aad5640","article-title":"MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations","volume":"8","author":"Arena","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.2025.43.4_suppl.197","article-title":"Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b\/2 study","volume":"43","author":"Raghav","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Tardito, S., Matis, S., Zocchi, M.R., Benelli, R., and Poggi, A. (2024). Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137131"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s12672-025-03569-x","article-title":"Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:12:04Z","timestamp":1775441524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":152,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073265"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073265","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}